

Camilla TÃndel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8803295/publications.pdf>

Version: 2024-02-01

43
papers

2,137
citations

361413

20
h-index

315739

38
g-index

45
all docs

45
docs citations

45
times ranked

2531
citing authors

#	ARTICLE	IF	CITATIONS
1	Long COVID in a prospective cohort of home-isolated patients. <i>Nature Medicine</i> , 2021, 27, 1607-1613.	30.7	453
2	Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 36.	2.7	239
3	Safety and Complications of Percutaneous Kidney Biopsies in 715 Children and 8573 Adults in Norway 1988–2010. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1591-1597.	4.5	206
4	Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 137-148.	6.1	202
5	Renal Biopsy Findings in Children and Adolescents With Fabry Disease and Minimal Albuminuria. <i>American Journal of Kidney Diseases</i> , 2008, 51, 767-776.	1.9	173
6	Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. <i>Kidney International</i> , 2011, 79, 663-670.	5.2	138
7	European expert consensus statement on therapeutic goals in Fabry disease. <i>Molecular Genetics and Metabolism</i> , 2018, 124, 189-203.	1.1	122
8	Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 242-247.	1.1	51
9	The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease – A systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 212-223.	1.1	50
10	Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1470-1479.	4.5	42
11	Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0124987.	2.5	42
12	Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100014.	5.6	39
13	One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. <i>PLoS ONE</i> , 2016, 11, e0152812.	2.5	38
14	Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw094.	0.7	34
15	Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1507-1513.	0.7	31
16	SARS-CoV-2–Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 589-599.	4.0	31
17	Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease. <i>PLoS ONE</i> , 2014, 9, e112188.	2.5	29
18	Pathomechanisms of renal Fabry disease. <i>Cell and Tissue Research</i> , 2017, 369, 53-62.	2.9	27

#	ARTICLE	IF	CITATIONS
19	Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial. <i>Molecular Genetics and Metabolism</i> , 2019, 127, 86-94.	1.1	25
20	Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. <i>Pediatric Nephrology</i> , 2019, 34, 301-311.	1.7	23
21	Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. <i>Pediatric Nephrology</i> , 2017, 32, 311-320.	1.7	21
22	Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. <i>Pediatric Nephrology</i> , 2018, 33, 683-696.	1.7	16
23	Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation. <i>Disease Markers</i> , 2020, 2020, 1-8.	1.3	15
24	Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study. <i>Neurourology and Urodynamics</i> , 2021, 40, 1490-1499.	1.5	15
25	Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 710-6.	1.2	11
26	The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. <i>Journal of Pediatric Urology</i> , 2020, 16, 31.e1-31.e10.	1.1	9
27	Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 317-323.	2.0	9
28	Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with fabry disease and microalbuminuria. <i>Clinical Therapeutics</i> , 2008, 30, S42.	2.5	6
29	Low birthweight is associated with lower glomerular filtration rate in middle-aged mainly healthy women. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 92-99.	0.7	6
30	Reduced Î±-galactosidase A activity in zebrafish (<i>Danio rerio</i>) mirrors distinct features of Fabry nephropathy phenotype. <i>Molecular Genetics and Metabolism Reports</i> , 2022, 31, 100851.	1.1	6
31	Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase-Associated Lipocalin in Children. <i>Journal of Applied Laboratory Medicine</i> , 2017, 2, 297-308.	1.3	5
32	Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis. <i>Blood</i> , 2021, 138, 516-516.	1.4	4
33	Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2022, 111, 391-400.	1.5	3
34	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. <i>Communications Medicine</i> , 2022, 2, .	4.2	3
35	1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S671-S671.	0.9	3
36	A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease. <i>Kidney International</i> , 2022, 102, 173-182.	5.2	3

#	ARTICLE	IF	CITATIONS
37	Measurement of renal functional response using iohexol clearance—a study of different outpatient procedures. CKJ: Clinical Kidney Journal, 2021, 14, 181-188.	2.9	1
38	MP042BENEFICIAL EFFECTS ON PODOCYTE GLOBOTRIAOSYLCERAMIDE DEPOSITS IN SERIAL KIDNEY BIOPSIES OF FABRY CHILDREN AND ADULTS AFTER UP TO 13 YEARS OF ENZYME REPLACEMENT. Nephrology Dialysis Transplantation, 2016, 31, i356-i356.	0.7	0
39	FP771IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR. Nephrology Dialysis Transplantation, 2018, 33, i305-i306.	0.7	0
40	SP035CLINICAL CONSEQUENCES OF PAIRED CARDIAC AND KIDNEY BIOPSIES IN A TREATMENT NAÏVE FEMALE FABRY PATIENT WITH A CLASSICAL MUTATION AND MINOR CLINICAL SYMPTOMS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
41	MO127CLEARED PODOCYTES AND NORMAL KIDNEY FUNCTION IN CLASSICAL FABRY MALES 15 YEARS AFTER START OF ENZYME REPLACEMENT THERAPY AT YOUNG AGE*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
42	Cardiovascular changes in young renal failure patients. CKJ: Clinical Kidney Journal, 2022, 15, 183-185.	2.9	0
43	Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination. Scientific Reports, 2021, 11, 23224.	3.3	0